Yale takes CRISPR beyond editing, turning cold tumors hot

Yale team aims CRISPR at tumor cells in an editing-free vaccine that boosts neoantigen production

A Yale team has developed a new use for CRISPR as a cancer vaccine that turns cold tumors hot by boosting neoantigen expression, rather than editing genes.

In the realm of cancer, CRISPR’s application to drug development has primarily been in target discovery and ex vivo

Read the full 455 word article

User Sign In